Evidence map›Paper›PMID 40299452›Full record

ArticleBiomedicines2025

Novel mRNA-Engineered Fully Human CAR-T Cells Targeting AXL in Solid Tumors.

Bo Zou, Mengge Wang, Shimeng Bai, Ning Li, Zhongyi Fan, Yuanzheng Peng, Mingshu Han, Chen Zeng, Hongzhou Lu, Lin Qi and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Bo ZouShenzhen Key Laboratory for Systems Medicine in Inflammatory Diseases, School of Medicine, Sun Yat-sen University, Shenzhen Campus, Shenzhen 518106, China.
Mengge WangInstitute of Advanced Biotechnology and School of Medicine, Southern University of Science and Technology, Shenzhen 518055, China.
Shimeng BaiBiotherapy Clinical Research Center, Shenzhen Third People's Hospital, The Second Affiliated Hospital to Southern University of Science and Technology, Shenzhen 518112, China.
Ning LiBiotherapy Clinical Research Center, Shenzhen Third People's Hospital, The Second Affiliated Hospital to Southern University of Science and Technology, Shenzhen 518112, China.
Zhongyi FanBiotherapy Clinical Research Center, Shenzhen Third People's Hospital, The Second Affiliated Hospital to Southern University of Science and Technology, Shenzhen 518112, China.
Yuanzheng PengKidney Transplant Department (Liver Transplant Department), Transplant Center, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, The Second Affiliated Hospital to Southern University of Science and Technology, Shenzhen 518112, China.
Mingshu HanBiotherapy Clinical Research Center, Shenzhen Third People's Hospital, The Second Affiliated Hospital to Southern University of Science and Technology, Shenzhen 518112, China.
Chen ZengInstitute of Advanced Biotechnology and School of Medicine, Southern University of Science and Technology, Shenzhen 518055, China.
Hongzhou LuNational Clinical Research Centre for Infectious Diseases, Shenzhen Third People's Hospital, The Second Affiliated Hospital to Southern University of Science and Technology, Shenzhen 518112, China.
Lin QiShenzhen Key Laboratory for Systems Medicine in Inflammatory Diseases, School of Medicine, Sun Yat-sen University, Shenzhen Campus, Shenzhen 518106, China.ORCID 0000-0003-2491-2701
Xingding ZhangShenzhen Key Laboratory for Systems Medicine in Inflammatory Diseases, School of Medicine, Sun Yat-sen University, Shenzhen Campus, Shenzhen 518106, China.ORCID 0000-0002-2759-5185
Xiaohua TanBiotherapy Clinical Research Center, Shenzhen Third People's Hospital, The Second Affiliated Hospital to Southern University of Science and Technology, Shenzhen 518112, China.
Qibin LiaoBiotherapy Clinical Research Center, Shenzhen Third People's Hospital, The Second Affiliated Hospital to Southern University of Science and Technology, Shenzhen 518112, China.ORCID 0009-0003-6024-9430

Funding

Fund of Shenzhen Key Laboratory ZDSYS20220606100803007Guangdong Natural Science Foundation of China 2022A1515012286, 2022A1515012252National Key Research and Development Program of China 2022YFC2304401, 2022YFC2304402National Natural Science Foundation of China 82402147, 32170789, 32100563Shenzhen High-level Hospital Construction Fund G2022091, XKJS-CRGRK-008Shenzhen Science and Technology Program RCBS20221008093104016, JCYJ20220530145217039, JCYJ20220530145217040Special Funds for Strategic Emerging Industry of Shenzhen F-2022-Z99-502266
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AXLfully human CAR-TimmunotherapymRNAsolid tumors

Identifiers

PMID40299452
PMCPMC12024984

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.